Improving high-fat diet-induced obesity and fatty liver by adipose tissue targeted delivery of vascular endothelial growth factor-B.

Abstract

Impaired vascularization of adipose tissue leads to local hypoxia and results in chronic inflammation and obesity-related metabolic disorders. We have recently constructed an engineered protein named tPep-VEGF-B by bridging vascular endothelial growth factor (VEGF-B) with an adipose-targeted peptide. Here, we reported tPep-VEGF-B diminishes obesity and alleviates metabolic syndrome. High fat diet (HFD) treated mice had reduced adipose vascular density and showed adipose hypoxia and metabolic complications. In contrast, the treatment of tPep-VEGF-B repressed HFD-induced body weight gain, which led to increased adipose vasculature and reduced hypoxia. This treatment also alleviated obesity associated hyperlipidemia and fatty liver disease. This study provided a leading molecule for the treatment of type 2 diabetes and other metabolic diseases. It also provided experimental support for the theory that modulation of angiogenesis plays a key role in the treatment of metabolic diseases.

• Authors: Yue Tong, Yu Zhang, Zhenzhen Shan, Yueming Xu, Xiangdong Gao, Wenbing Yao
• Journal: Life sciences (Life Sci) Vol. 253 Pg. 117677 (Jul 15 2020) ISSN: 1879-0631 [Electronic] Netherlands
• PMID: 32305525 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Elsevier Inc. All rights reserved.

Chemical References

• Peptides
• Vascular Endothelial Growth Factor B

Topics

• Adipose Tissue (blood supply)
• Animals
• Diet, High-Fat (adverse effects)
• Disease Models, Animal
• Drug Delivery Systems
• Fatty Liver (prevention & control)
• Hyperlipidemias (prevention & control)
• Male
• Mice
• Mice, Inbred C57BL
• Obesity (prevention & control)
• Peptides (chemistry)
• Vascular Endothelial Growth Factor B (administration & dosage, pharmacology)